Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0B4XX
|
|||
Former ID |
DIB003908
|
|||
Drug Name |
QR-333
|
|||
Indication | Diabetic neuropathy [ICD-11: 8C0Z; ICD-10: G63, G63.2] | Phase 2 | [1] | |
Company |
Quigley Pharma Inc
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Aldose reductase (AKR1B1) | Target Info | Inhibitor | [2] |
BioCyc | Methylglyoxal degradation III | |||
Acetone degradation I (to methylglyoxal) | ||||
KEGG Pathway | Pentose and glucuronate interconversions | |||
Fructose and mannose metabolism | ||||
Galactose metabolism | ||||
Glycerolipid metabolism | ||||
Metabolic pathways | ||||
NetPath Pathway | IL1 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Pathwhiz Pathway | Fructose and Mannose Degradation | |||
Pyruvate Metabolism | ||||
Pterine Biosynthesis | ||||
Glycerolipid Metabolism | ||||
Galactose Metabolism | ||||
WikiPathways | Metapathway biotransformation | |||
Polyol Pathway | ||||
Metabolism of steroid hormones and vitamin D |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00568035) Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy. U.S. National Institutes of Health. | |||
REF 2 | A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.